Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571622 | PMC |
| http://dx.doi.org/10.1177/19322968241293810 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Glucagon-like Peptide-1-Based Therapies Do Not Interfere With Blood Glucose Monitoring Systems.
J Diabetes Sci Technol
January 2025
Roche Diabetes Care GmbH, Mannheim, Germany.
Changes in 24-Hour Urine Chemistry in Patients with Nephrolithiasis during Weight Loss with Glucagon-Like Peptide 1-Based Therapies.
Kidney360
November 2024
Department of Internal Medicine, Division of Endocrinology, UT Southwestern Medical Center, Dallas, Texas.
GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review.
EClinicalMedicine
September 2024
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Despite the availability of a wide range of antihypertensive agents, a significant proportion of individuals with resistant hypertension (RHTN) struggle to achieve blood pressure (BP) control. Obesity ranks among the most significant modifiable risk factors for RHTN, with 56-91% of patients with RHTN classified as overweight or obese. Glucagon-like peptide-1 receptor agonist (GLP-1 RAs) are a class of anti-obesity medications that have recently demonstrated efficacy in reducing BP and improving cardiovascular (CV) outcomes in individuals with overweight or obesity.
View Article and Find Full Text PDFOpportunities to optimize lifestyle interventions in combination with glucagon-like peptide-1-based therapy.
Diabetes Obes Metab
September 2024
Division of Endocrinology, University Health Network & University of Toronto, Toronto General Hospital, Toronto, Ontario, Canada.
Obesity is a chronic multi-system disease and major driver of type 2 diabetes and cardiometabolic disease. Nutritional interventions form the cornerstone of obesity and type 2 diabetes management. Some interventions such as Mediterranean diet can reduce incident cardiovascular disease, probably independently of weight loss.
View Article and Find Full Text PDFThe benefits of GLP-1 drugs beyond obesity.
Science
July 2024
The Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, and the Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Glucagon-like peptide-1-based medicines have weight loss-independent actions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!